Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pabst

Showing results (241-250 of 332) with videos related to

Pageof 34
Sort By:
Blood Cancer Journal|March 28, 2024
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trialNiek G van der Maas, Jurjen Versluis, Kazem Nasserinejad, et al.
Blood|April 23, 2020
Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 studyCorentin Orvain, Marie Balsat, Emmanuelle Tavernier, et al.
Neurology|November 8, 2014
Sporadic late-onset nemaline myopathy with MGUS: long-term follow-up after melphalan and SCTNicol C Voermans, Olivier Benveniste, Monique C Minnema, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categoriesJan J Cornelissen, Dimitri Breems, Wim L J van Putten, et al.
Acta Haematologica|December 2, 2025
Hemophagocytic Syndromes in Adults: Real-World Data on Mortality from a Tertiary Reference CenterTatiana Wojtovicova, Drahomir Aujesky, Joerg C Schefold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03Christian Taverna, Giovanni Martinelli, Felicitas Hitz, et al.
Transfusion|June 27, 2014
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxideCurly Morris, Liesbeth de Wreede, Marijke Scholten, et al.
Blood Advances|December 4, 2020
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trialAlden A Moccia, Christian Taverna, Sämi Schär, et al.
Cancer Medicine|December 25, 2021
The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzedKaterina Bakunina, Hein Putter, Jurjen Versluis, et al.
The New England Journal of Medicine|March 18, 2011
Cytarabine dose for acute myeloid leukemiaBob Löwenberg, Thomas Pabst, Edo Vellenga, et al.
Pageof 34

Showing results (241-250 of 332) with videos related to

Sort By:
Pageof 34
Blood Cancer Journal|March 28, 2024
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trialNiek G van der Maas, Jurjen Versluis, Kazem Nasserinejad, et al.
Blood|April 23, 2020
Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 studyCorentin Orvain, Marie Balsat, Emmanuelle Tavernier, et al.
Neurology|November 8, 2014
Sporadic late-onset nemaline myopathy with MGUS: long-term follow-up after melphalan and SCTNicol C Voermans, Olivier Benveniste, Monique C Minnema, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categoriesJan J Cornelissen, Dimitri Breems, Wim L J van Putten, et al.
Acta Haematologica|December 2, 2025
Hemophagocytic Syndromes in Adults: Real-World Data on Mortality from a Tertiary Reference CenterTatiana Wojtovicova, Drahomir Aujesky, Joerg C Schefold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03Christian Taverna, Giovanni Martinelli, Felicitas Hitz, et al.
Transfusion|June 27, 2014
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxideCurly Morris, Liesbeth de Wreede, Marijke Scholten, et al.
Blood Advances|December 4, 2020
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trialAlden A Moccia, Christian Taverna, Sämi Schär, et al.
Cancer Medicine|December 25, 2021
The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzedKaterina Bakunina, Hein Putter, Jurjen Versluis, et al.
The New England Journal of Medicine|March 18, 2011
Cytarabine dose for acute myeloid leukemiaBob Löwenberg, Thomas Pabst, Edo Vellenga, et al.
Pageof 34